The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older. READ MORE
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
The FDA has approved the first treatment for a type of localized prostate cancer, using a novel endpoint to support the approval.
Researchers presenting at the 2018 ASCO Genitourinary Cancers Symposium compared the costs associated with two different approaches to management of low-risk prostate cancer and gave a recommendation toward a value-based care model.
The FDA has approved a hormone-based chemotherapy in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Research in Review
Positron emission tomography and computed tomography scans specific to prostate cancer can detect further disease and improve clinical management.
The United States Preventive Services Task Force released a statement that prostate-specific antigen-based screening for prostate cancer should be avoided in men aged 70 years and older.
ASCO Issues New Guidelines for Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer
The American Society of Clinical Oncology has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy for metastatic prostate cancer that has not been treated with testosterone-lowering agents.
The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.